Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) announced plans to acquire Kelonia Therapeutics for approximately $7 billion, a move intended to strengthen its gene therapy pipeline. The company reported a year-over-year revenue increase of 43% and earnings per share growth of 51% during the fourth quarter. Its current forward-looking price-to-earnings (P/E) ratio stands at 40, below its five-year average of 56. With health spending growing by 7.2% from 2023 to 2024, managing competition in the weight-loss sector remains crucial for Lilly's future growth.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
- Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
- Lilly (LLY) obesity pill reduces cardiovascular risks in trial
- Eli Lilly (LLY) market share drops to 56% in India as generics flood
- Senator Angus King Jr. Sells $1,000 to $15,000 in Autodesk (ADSK)
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
